Why the study?
Patients with rheumatoid arthritis are at greater risk of incident heart failure, and targeting innate immune cell function may guide the development of future therapies.
Does PAD4 inhibition with JBI-589 prevent inflammation-mediated heart failure in a mouse model of rheumatoid arthritis?
Population
DBA/1 J mice with collagen-induced arthritis
Comparison
Oral protein arginine deiminase 4 inhibitor (JBI-589) vs uninhibited arthritis
Design
Preclinical animal study
Authors
Loading...
Associates RA inflammation with concentric HF remodeling in mice; leaves open clinical relevance of innate immune targeting for HF prevention.
Does PAD4 inhibition with JBI-589 prevent inflammation-mediated heart failure in a mouse model of rheumatoid arthritis?
Inhibition of PAD4 prevents adverse myocardial remodeling and diastolic dysfunction in a mouse model of rheumatoid arthritis, identifying a potential therapeutic target for inflammation-mediated heart failure.
Heger et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: